Abstracts

Neurodevelopment in Children Exposed In Utero to Dolutegravir- or Efavirenz-Based ART in Botswana

Background: Dolutegravir (DTG)- and, to a lesser extent, efavirenz (EFV)- based antiretroviral treatment (ART) regimens are commonly used by pregnant persons living with HIV in high burden HIV settings, increasingly with initiation prior to conception. Little is known about the impact of in utero exposure to DTG- or EFV-based ART on child neurodevelopmental (ND) outcomes,…

Brain Structure of South African HEU Children Exposed to Dolutegravir Versus Efavirenz

Background: Current research suggests that children who are HIV-exposed and uninfected (CHEU) may be at risk for neurodevelopmental delay and altered structural brain development compared to children who are HIV-unexposed (CHU), however the specific factors driving this association and the potential role of specific antiretroviral regimens are poorly understood. In particular volumes of specific regions…

Maternal Imprinted Immune Perturbations in HIV-Exposed Uninfected (HEU) Infants Persist for 6 Months

Background: HEU infants exhibit higher mortality/morbidity including adverse growth, developmental, infectious, and metabolic outcomes, and perturbed immune responses. How their immune profiles are altered and influenced by maternal immunity is unknown. Methods: The study group included 46 pregnant women with HIV (PWH)/HEU infant pairs enrolled in PACTG 316, with 23 PWH virally suppressed (VS) during…

First Trimester Exposure to Newer Antiretroviral Agents and Congenital Anomalies in a US Cohort

Background: The teratogenicity of antiretroviral medications (ARVs) is a key consideration in clinical recommendations and prescribing decisions for HIV regimens used during pregnancy. However, in the U.S., data on the association between ARV exposures and major congenital anomalies are generally limited to older ARV agents, many of which are now rarely used. Given the timing…

Dolutegravir Versus Efavirenz: Depression, Anxiety, and Sleep Disorders in Pregnancy and Postpartum

Background: Both integrase strand transferase-inhibitors and non-nucleoside reverse transcriptase-inhibitors such as dolutegravir and efavirenz, respectively, are known to be effective in pregnancy and post-partum to prevent vertical transmission of HIV and to maintain maternal health. Both drugs have also been associated with neuropsychiatric symptoms such as depression, anxiety and sleep disorders. To what extent these…

Breast Milk Transfer and Infant Exposures to DTG, TAF, and TFV: Results From IMPAACT 2010/VESTED

Background: Limited information is available on breast milk transfer and subsequent infant systemic exposure to dolutegravir (DTG), tenofovir alafenamide (TAF), and tenofovir (TFV). We evaluated concentrations of these antiretroviral (ARV) drugs in time-matched samples (maternal plasma, breast milk, and infant plasma) in a post hoc analysis of IMPAACT 2010, a randomized trial that evaluated three…

Budget Impact Analysis of an Enhanced Retention Strategy for PMTCT Programs in Uganda

Background: Novel retention strategies have the potential to reduce mother-to-child transmission and improve patient outcomes for people living with HIV. The enhanced retention strategy (ERS) of the DolPHIN-2 trial in Uganda achieved a retention rate of 92% among women receiving PMTCT services and reduced perinatal transmission (PT) from 2.8% (national rate) to 1.5% (DolPHIN cohort).…